Patents by Inventor William McCoull

William McCoull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC DENDRIMERS
    Publication number: 20240115716
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: June 14, 2023
    Publication date: April 11, 2024
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 11717574
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: August 8, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William Mccoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • THERAPEUTIC DENDRIMERS
    Publication number: 20210060172
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 10888624
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • THERAPEUTIC DENDRIMERS
    Publication number: 20200069810
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: April 5, 2019
    Publication date: March 5, 2020
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Therapeutic dendrimers
    Patent number: 10314920
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 11, 2019
    Assignee: AstraZeneca AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • THERAPEUTIC DENDRIMERS
    Publication number: 20180264127
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Application
    Filed: February 20, 2018
    Publication date: September 20, 2018
    Inventors: Marianne Bernice ASHFORD, Iain GRANT, Edward John HENNESSY, William MCCOULL, Michael GIANNIS, Brian KELLY, David OWEN, John Paul SECRIST
  • Chemical compounds
    Patent number: 8673938
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: March 18, 2014
    Assignee: AstraZeneca AB
    Inventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • THERAPEUTIC AGENTS
    Publication number: 20120115845
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 10, 2012
    Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood
  • Chemical compounds
    Patent number: 7964618
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: June 21, 2011
    Assignee: AstraZeneca AB
    Inventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS
    Publication number: 20110124621
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: October 8, 2008
    Publication date: May 26, 2011
    Inventors: Jack McQueen Allen, Roger John Butlin, Clive Green, William Mccoull, Graeme Richard Robb, James Matthew Wood
  • OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
    Publication number: 20100317653
    Abstract: Compounds of formula (I), and salts and pro-drugs thereof: wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    Type: Application
    Filed: August 3, 2010
    Publication date: December 16, 2010
    Applicant: AstraZeneca AB
    Inventors: Alan Martin BIRCH, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William Mccoull, Thorsten Nowak, Alleyn Plowright
  • Oxadiazole derivative as DGAT inhibitors
    Patent number: 7795283
    Abstract: Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: September 14, 2010
    Assignee: AstraZeneca AB
    Inventors: Alan Martin Birch, Suzanne Saxon Bowker, Roger John Butlin, Craig Samuel Donald, William McCoull, Thorsten Nowak, Alleyn Plowright
  • PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY
    Publication number: 20100048543
    Abstract: The invention relates to a compound of the Formula I or salt thereof wherein Rx, Ry, Rz, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm-blooded animal. The invention also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: January 27, 2006
    Publication date: February 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Clifford David Jones, Richard Williams Arthur Luke, William McCoull
  • PYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE FOR INHIBITING 11-BETA-HYDROXYSTEROID DEHYDROGENASE
    Publication number: 20100022589
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Application
    Filed: July 26, 2007
    Publication date: January 28, 2010
    Inventors: William McCoull, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • CHEMICAL COMPOUNDS
    Publication number: 20090312372
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Application
    Filed: August 14, 2009
    Publication date: December 17, 2009
    Applicant: AstraZeneca AB
    Inventors: William MCCOULL, Martin PACKER, James Stewart SCOTT, Paul Robert Owen WHITTAMORE
  • CHEMICAL COMPOUNDS
    Publication number: 20090306075
    Abstract: Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are described.
    Type: Application
    Filed: August 14, 2009
    Publication date: December 10, 2009
    Applicant: AstraZeneca AB
    Inventors: William MCCOULL, Martin Packer, James Stewart Scott, Paul Robert Owen Whittamore
  • OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
    Publication number: 20090215779
    Abstract: Compounds of Formula (I): wherein R1-R2, W and Y are as described in the specification, and their salts and pro-drugs, are inhibitors of DGAT and are thereby useful in the treatment of, for example, obesity. Processes for preparing compounds of formula (I) are also described.
    Type: Application
    Filed: June 6, 2006
    Publication date: August 27, 2009
    Inventors: Roger John Butlin, Clive Philip Green, William McCoull
  • CHEMICAL COMPOUNDS
    Publication number: 20090209602
    Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA(acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein, for example, R1 is an optionally substituted aryl or optionally substituted heteroaryl group, Y is a direct bond, or a defined linking group and R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.
    Type: Application
    Filed: June 4, 2007
    Publication date: August 20, 2009
    Inventors: Roger John Butlin, Robert Davies, William McCoull
  • Therapeutic Agents - 802
    Publication number: 20090186870
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1, R2, R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.
    Type: Application
    Filed: October 9, 2008
    Publication date: July 23, 2009
    Applicant: AstraZeneca AB
    Inventors: Jack McQueen ALLEN, Roger John Butlin, Clive Green, William McCoull, Graeme Richard Robb, James Matthew Wood